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Abbreviation 
mDC1, myeloid dendritic cells 1; HCs, healthy controls; MoDCs, monocyte-derived 
dendritic cells; PBMCs, peripheral blood mononuclear cells; Th, T helper; DCs, dendritic 
cells; mDCs, myeloid dendritic cells; pDCs, plasmacytoid dendritic cells; Lin1, lineage 1; 
Alb, albumin; iNKT, invariant natural killer T. 
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Abstract  
 
In this study we investigated the role of blood CD1c+ myeloid dendritic cells 1 (mDC1), a 
key mDC subtype, in patients with autoimmune uveitis. We observed a significant 
increase of blood CD1c+ mDC1 in uveitis patients. The increased CD1c+ mDC1 exhibited 
high HLADR expression and less antigen uptake. CD1c+ mDC1 were divided into two 
subpopulations. CD1chi mDC1 subpopulation showed less antigen uptake and higher 
HLADR expression compared to CD1clo mDC1 subpopulation. Importantly, the CD1chi 
mDC1 subpopulation was increased in uveitis patients. In vitro, mature monocyte-
derived dendritic cells (MoDCs), characterized by lower levels of antigen uptake, 
induced more CD62L-CD4+ T helper cell proliferation. The mature phenotype and 
function of CD1c+ mDC1 were regulated by TNF via a p38 MAPK-dependent pathway. 
These data show that alterations in the systemic immune response are involved in the 
pathogenesis of autoimmune uveitis and invite the therapeutic possibility of attenuating 
uveitis by manipulating blood CD1c+ mDC1. 
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1. Introduction  
 
Human autoimmune ocular inflammatory diseases, particularly non-infectious uveitis 
(abbreviated as uveitis), are currently responsible for 10% of the visual handicap in the 
United States [1]. The most commonly recognized mechanism of uveitis is CD4+ T 
helper (Th) cell mediated immune dysregulation [2-4]. It has been suggested that the 
immune dysregulation is characterized by the imbalance between regulatory and 
pathogenic effector T cells, increased inflammatory and decreased anti-inflammatory 
cytokines, hyper-responsiveness to self-antigens, and dysfunctional dendritic cells 
(DCs), which are all suspected to contribute to the pathogenesis of autoimmune disease 
[5]. 
        Dendritic cells (DCs) play a central role in immune regulation since they are 
involved in both innate and adaptive immune responses. An indispensable part of 
initiating the immune response in the eye is the permeability of the blood-ocular barrier 
to inflammatory cells. Infiltrating cells include monocytes/macrophages, lymphocytes, 
neutrophils, and myeloid DCs (mDCs). Moreover, an emerging body of literature 
supports a pivotal role for mDCs in uveitis in humans and mice [6-8]. However, the 
actual source of mDCs in eye tissue, along with the factors that trigger DC maturation, 
take up antigens and help T cell responses, remain unidentified. 
        DCs are derived from either progenitors in the bone marrow or monocytes in the 
peripheral blood. Blood DCs contain three subsets: CD1c+ (BDCA1) myeloid dendritic 
cell 1 (mDC1), CD141+ (BDCA3) myeloid dendritic cell 2 (mDC2), and CD303+ (BDCA2) 
plasmacytoid DCs (pDCs) [9], which are from Lineage 1- (Lin1, including CD3, CD14, 
CD16, CD19, CD20 and CD56) HLADR+ cells. Myeloid DCs actively infiltrate into the 
eye and can be seen suspending in the aqueous humor of uveitis patients [10].  
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        In this study, we observed an increase in blood CD1c+ mDC1 with enhanced 
HLADR expression and lower levels of antigen uptake indicating a more mature 
phenotype. Moreover, this was associated with an increase in a subpopulation of CD1chi 
mDC1, which had very low levels of antigen uptake. In an in vitro model we observed 
that MoDCs with a similar low-antigen-uptake phenotype promoted more CD4+ T cell 
proliferation, than those taking up high levels of antigen. Our work also supports the 
hypothesis that in uveitis the mature phenotype of CD1c+ mDC1 were regulated by 
TNF via a p38 MAPK-dependent pathway.  
 
2. Material and methods 
2.1. Study population 
 
Peripheral blood was obtained from patients with non-infectious uveitis (n=74) in the 
Clinical Center of the National Eye Institute (NEI), and from healthy controls (HCs, n=96) 
in the Blood Bank of the National Institutes of Health (NIH). All protocols were approved 
by the NIH Neuroscience Institutional Review Board (IRB). Informed consents were 
obtained from all subjects before the study commenced. Ocular disease activity, i.e. 
active and inactive uveitis, were recorded according to the Standardization of Uveitis 
Nomenclature (SUN) [11]. According to SUN criteria, less than one cell, or alternatively, 
no flare in the anterior chamber, constitutes a graded score of 0. SUN criteria go on to 
address “trace” cells in the vitreous, correlating this clinical impression with a score of 
0.5. A grade of 0 is regarded as inactive, whereas, a grade  0.5 is considered slightly 
active, and a grade  1 or haze in vitreous is considered active. Here, we put slightly 
active and active uveitis into one group as “active”.  
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        To investigate the phenotype and function of mDC1 in the peripheral blood, the 
effects of systemic immunosuppressive therapy on mDC1 were considered. The 
presence or absence of systemic immunosuppressive therapy was thus documented; 
this included systemic corticosteroids, secondary immunomodulatory therapy and 
biologic response modifiers (see the table).  
 
2.2. Identification of mDCs and pDCs in human peripheral blood  
 
Blood DCs were identified by 4-color staining performed on whole fresh peripheral blood 
using the following monoclonal antibodies: PE-CD1c (BDCA1, Miltenyi Biotec, Auburn, 
CA) or PE-CD141 (BDCA3, Miltenyi Biotec), PERCP-HLADR (Miltenyi Biotec), APC-
CD303 (BDCA2, Miltenyi Biotec), and FITC-labeled mAbs against lineage markers CD3, 
CD14, CD16, CD19, CD20 and CD56 (BD Biosciences, San Jose, CA).  Cells that were 
not labeled with these lineage markers were designated as Lin1-. Myeloid DC1 were 
CD1c+, mDC2 were CD141+, and pDCs were CD303+. These DCs were gated on Lin1-
HLADR+ total DC population. Cells were analyzed on FACSCalibur (BD Biosciences). 
DC number was calculated by multiplying the percentage of DCs by the total number of 
white blood cells (WBC) in 1 ml blood (DC number = % of DCs  number of WBC/ml). 
 
2.3. Generation of monocyte-derived DCs 
 
Monocyte-derived dendritic cells (MoDCs) were generated as previously described and 
used as an in vitro model for mDCs for additional functional studies [12, 13]. Briefly, 
monocytes were isolated from mononuclear cell fractions of the peripheral blood of 
healthy controls and seeded in the presence of GM-CSF (40 ng/ml; R&D systems, 
Minneapolis, MN) and IL-4 (20 ng/ml; R&D Systems) at a concentration of 1  106 
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cells/well in a 6-well plate. Six to seven days after culture, monocytes were completely 
differentiated into dendritic cells and CD1c expression was evaluated by flow cytometry. 
        To investigate the effect of the TNFα-p38 MAPK signaling pathway on CD1c 
expression, recombinant TNFα (10 ng/ml, R&D, Minneapolis, MN) was added for 24 
hours before measuring the protein expression of CD1c, and for 30 minutes before 
measuring phosphoryrated-p38 MAPK (BD Biosciences) expression on MoDCs by flow 
cytometry. For blocking experiments, the selective MAPK inhibitor SB203580 (10 mol/l, 
Cell Signaling, Danvers, MA) was added at day 0 of MoDCs differentiation in vitro. CD1c 
protein expression was measured by flow cytometry on days 1, 3, and 5.  
 
2.4. Evaluation of cytokine production 
 
Peripheral blood were stimulated with lipopolysaccharides (LPS, 1 g/ml, Sigma-Aldrich, 
St. Louis, MO) and GolgiPlugTM (2 l/ml, BD Pharmingen, San Jose, California) for 5 h at 
37°C in a humidified 5% CO2 atmosphere. Following stimulation, cells were stained with 
Lin1, HLADR and CD1c to identify mDC1. Then, cells were fixed and permeabilized (Fix 
& Perm Cell Permeabilization Kit; BD Biosciences) before staining for IL6, IL10 and 
IL12p40/70 (BD Biosciences). Cytokine production was analyzed by flow cytometry. 
 
2.5. Antigen uptake assay 
 
Quantitative analysis of DC endocytosis was performed as described previously [14], 
with minor modifications. To study mDC endocytosis, 1ml of fresh blood was incubated 
with FITC-albumin (10 μg/ml, Sigma-Aldrich, St, Louis, Mo) at either 37 or 4°C (as 
negative control) for 30 minutes. Freshly taken blood was stained with CD1c, HLADR 
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and CD19, followed by flow cytometric analysis. The CD1c+HLADR+CD19- population 
was classified as mDC1. Myeloid DC1 expressing FITC represented mDC1 taking up 
antigen (albumin). In the functional studies, 1µl sera from HC or uveitis patients was 
added into MoDCs in the volume of 200 µl for 24 hours before the antigen uptake assay 
was conducted. To investigate the effect of TNF on antigen uptake, MoDCs were 
treated with recombinant TNF at different concentrations (0.1 ng/ml, 1 ng/ml and 10 
ng/ml) for 24 hours. The antigen uptake assay was subsequently conducted.  
 
2.6. DC-stimulated T cell responses 
 
MoDCs-stimulated T cell responses were performed as described previously [14], with 
minor modifications. Briefly, MoDCs with high albumin uptake (Alb+) and low albumin 
uptake (Alb-) were sorted based on FITC-albumin expression on MoDCs. Magnetic bead 
separation (Miltenyi Biotec) was used to isolate CD4+ T cells in peripheral blood 
mononuclear cells (PBMCs) from healthy controls. Purity of isolated fractions 
consistently averaged to be >95% for CD4+ T cells. Isolated DCs were co-cultured with 
CFSE-labeled allogenic CD4+ T cells at a ratio of 1:10 (DC:T) for 5 days with the help of 
anti-CD3 stimulation (1 µg/ml). CD4+ T cell proliferation was characterized by flow 
cytometric analysis (percentage of cells exhibiting CFSE fluorescence dilution) and 
negative expression of CD62L was characterized with activated CD4+ T cells. 
 
2.7. Statistical analysis 
 
Data is presented as mean ± SD. Results shown were representative of at least three 
independent experiments. Statistical comparisons were performed using the Student‟s t 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 9 
test for two groups, or ANOVA tests for analyzing more than two groups. P<0.05 was 
considered as significant. Analyses were accomplished using Prism 6 software 
(GraphPad Software, Inc., La Jolla, CA). 
 
3. Results 
3.1. Elevation of blood CD1c+ mDC1 in uveitis patients 
 
The percentages and absolute numbers of blood DC subsets were determined in uveitis 
patients and HCs. DC subsets are shown in figure 1A. Lin1-HLADR+ cells were defined 
as total DCs in which cells were subsequently identified as CD1c+ mDC1, CD141+ mDC2 
and CD303+ pDCs [9]. In uveitis patients, the frequency (p=0.0025) and number 
(p=0.026) of blood CD1c+ mDC1 were significantly increased (Fig.1B and C), and the 
frequency of blood pDCs was decreased as compared to the levels observed in HCs 
(data not shown). No differences of mDC2 were detected between uveitis patients and 
HCs (data not show). Furthermore, we categorized the CD1c+ mDC1 frequency based 
on therapy and disease status in uveitis patients. No difference was observed in 
untreated versus treated patients (Fig.1D). However, CD1c+ mDC1 were increased in 
active uveitis compared to quiescent uveitis (p=0.03, Fig.1E). In summary, increased 
CD1c+ mDC1 expression was independent of the direct effect from therapy but highly 
correlated with disease activity. Demographic data of the study subjects were listed in 
the table. 
 
3.2. Elevation of HLADR expression on CD1c+ mDC1 in uveitis patients 
 
To determine whether blood CD1c+ mDC1 were more mature in uveitis patients 
compared with HCs, HLADR and co-stimulatory molecules (CD80 and CD86) on blood 
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CD1c+ mDC1 were analyzed by flow cytometry. HLADR expression, a marker of 
maturation and antigen presentation, was significantly higher on CD1c+ mDC1 in uveitis 
patients compared to HCs (p=0.002, Fig. 2A). We sought to determine whether HLADR 
expression was affected by therapy or disease activity. Interestingly, HLADR expression 
was significantly higher in the untreated group compared to the treated group (p=0.0075) 
and HCs (p<0.0001, Fig. 2B), indicating that therapy suppressed HLADR expression. 
We further evaluated whether higher HLADR expression correlated to disease status. 
Unexpectedly, higher HLADR expression was observed in the quiescent uveitis patients 
(p=0.0009) not in the active uveitis patients, as compared to HCs (Fig. 2C). The higher 
level of HLADR expression in the quiescent patients was probably due to the lower rates 
of therapy in this group as higher HLADR expression levels were observed in quiescent 
patients when not on treatment (p=0.029, Fig.2D).  
        We hypothesized that CD1c+ mDC1 from patients might be hyperresponsive to 
additional stimulation. To test this we stimulated CD1c+ mDC1 with LPS overnight and 
then measured HLADR expression. The HLADR expression level was significantly 
higher in uveitis patients after additional LPS stimulation, as compared to that in patients 
without stimulation (p=0.01, Fig. 2E). The co-stimulatory markers CD80 and CD86 were 
similar on CD1c+ mDC1 between uveitis patients and HCs (data not shown).  
 
3.3. Impaired cytokine production of uveitic CD1c+ mDC1 upon additional 
TLR4 stimulation  
 
Previous studies have shown that DCs exhaust their capacity to produce cytokines after 
the induction of maturation [15]. Consequently, we examined whether mature CD1c+ 
mDC1 in uveitis patients also displayed a similar exhaustion pattern in cytokine 
production. To test this, IL6, IL10 and IL12p40/70 produced from CD1c+ mDC1 of uveitis 
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patients (n=12) and HCs (n=9) were detected by flow cytometry. Uveitis patients were 
randomly selected from the cohort along with appropriately age-matched and gender-
matched healthy controls. IL6 (Fig.3A), IL10 (Fig.3B) and IL12p40/70 (Fig.3C) 
production were similar between uveitis patients and HCs ex vivo. After overnight 
stimulation with LPS, the production of IL6 (p=0.0002, Fig.3A), IL10 (p=0.01, Fig.3B) and 
IL12p40/70 (p=0.01, Fig.3C) from mDC1 was significantly increased compared with the 
unstimulated group from HCs. The cytokine production was not significantly increased 
after LPS stimulation in uveitis patients when compared with the unstimulated group 
from uveitis (Fig. 3). The lack of in vitro responses to additional LPS stimulation 
suggests that cytokine production abilities of mature CD1c+ mDC1 from uveitis patients 
are exhausted.  
 
3.4. Lower antigen uptake by CD1c+ mDC1 and its subpopulation CD1chi 
mDC1 in uveitis patients  
 
The capacity of mDCs to take up antigens is an indicator of their level of maturation, with 
higher levels of antigen take-up in the immature state moving to an antigen presentation 
role (supported in part by increasing levels of HLADR) as the mDC matures [16]. We 
observed a significant decrease of antigen uptake in CD1c+ mDC1 in uveitis patients 
compared to HCs (p=0.04, Fig. 4A, B). Flow cytometric analysis showed that CD1c+ 
mDC1 contained two subpopulations, CD1chi and CD1clo mDC1 (Fig.4C). Interestingly, 
only 1% of CD1chi mDC1 took up antigens while 43% of CD1clo mDC1 took up antigens 
(Fig. 4D, E). Importantly, we observed that CD1chi mDC1 were increased in uveitis 
patients compared to HCs (p=0.001, Fig. 4F), indicating that the lower antigen uptake in 
the whole CD1c+ mDC1 population was likely due to the increased numbers of CD1chi 
mDC1 in the uveitis group. Furthermore, high expression of CD1c was associated with 
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higher expression of HLADR in both HCs (p=0.0001, Fig. 4G) and uveitis patients 
(p=0.002, Fig. 4H).  
 
3.5. In vitro model showed MoDCs with lower antigen uptake associated 
with higher T cell proliferation 
 
Having shown that patients with uveitis have higher levels of CD1c+ mDC1 and of the 
CD1chi subgroup, and that these mDCs have a relatively „mature‟ profile characterized 
by higher HLADR and lower antigen uptake, we wished to investigate the functional 
consequences of this. For our functional studies, we used MoDCs as a substitute for 
mDCs in an in vitro model [12, 13, 17]. Six to Seven days are usually needed for 
monocytes to fully differentiate into mDCs in vitro. This allowed us to observe the 
expression of CD1c on MoDCs during differentiation (Fig. 7C, D). MoDCs were loaded 
with FITC-albumin for 30 minutes and two subpopulations were sorted by flow cytometry 
based on their ability to take up antigens, which were FITC-albumin+ and FITC-albumin- 
MoDCs (Fig. 5A). We cultured allogenic CD4+ T cells with either Albumin+ or Albumin- 
MoDCs for 5 days. CD62L-CD4+ T cell (activated T cells) proliferation was significantly 
increased in the group of Albumin- MoDCs, as compared to the group of Albumin+ 
MoDCs. This was shown by the percentage of CFSE dilution on CD62L-CD4+ T dells 
(Fig. 5B, C), indicating that MoDCs with lower antigen uptake could induce more CD4+ T 
cell proliferation and activation.  
 
3.6. Uveitic sera and exogenous TNF reduced antigen uptake in MoDCs 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 13 
Having confirmed in our in vitro model that the MoDCs with lower antigen uptake 
(modeling the low-antigen-uptake mDC1 identified earlier) induced higher levels of T cell 
proliferation with a higher proportion of activated CD62L- T cells, we wished to 
investigate this further, specifically whether there was a factor in uveitis serum that might 
be inducing this more mature DC phenotype. In order to investigate this, we performed 
overnight incubation with MoDCs treated with the addition of sera from patients with 
uveitis or HCs. We found that MoDCs had less antigen uptake after they were treated 
with sera from uveitis patients compared with MoDCs treated with sera from HCs (Fig. 
6A, B and C).  
        We hypothesized that this might be related to higher levels of inflammatory 
cytokines such as TNF and IL-17a in patient sera. TNF is known to contribute to DC 
maturation, plays a key role in the pathogenesis of uveitis, is present at high 
concentration levels both in the aqueous humor and in the serum [18-22], and is a 
successful target in the treatment of uveitis [23]. Although less well-established IL17a 
has also shown to be increased in patients with uveitis, and an anti-IL17 agent, 
secukinumab, has been trialed for treatment of uveitis [24, 25]. We found that TNF, but 
not IL17a (data not shown), significantly reduced MoDCs‟ antigen uptake in a dose-
dependent manner (Fig.6D, E and F). Furthermore we found that treatment with TNF 
increased CD1c expression compared to controls (Fig.7A).  
        One of the key pathways that TNF exerts its effect is via phosphorylation of p38 
MAPK [26]. We hypothesized that TNF-induced upregulation of CD1c expression was 
mediated via this pathway. Treatment of MoDCs with TNF caused an increased 
phosphorylation of p38 MAPK (Fig.7B). Conversely, blockage of this pathway by addition 
of SB203580, an inhibitor of p38 MAPK (Fig.7C, D), inhibited CD1c expression during 
MoDC differentiation. Although monocytes don‟t express CD1c, CD1c expression was 
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induced in MoDCs on day 1 and increased dramatically every subsequent day of 
differentiation. The inhibition of CD1c expression by SB203580 was observed on day 1 
and reached statistical significance on days 3 and 5 (Fig. 7C, D). Taken together, this 
data suggests that the known increased TNF levels in patient sera induces a more 
mature DC phenotype characterized by high CD1c expression and less antigen uptake, 
and this is mediated (at least in part) by the p38 MAPK pathway.  
 
4. Discussion 
 
In this study, we have shown that blood CD1c+ mDC1 is increased in autoimmune non-
infectious uveitis patients compared with HCs. Blood CD1c+ mDC1 from uveitis patients 
show a mature phenotype, characterized by less antigen uptake and high HLADR 
expression. CD1chi mDC1 is identified as the mDC1 subpopulation with lower antigen 
uptake, and associated with higher HLADR expression and a capability to induce higher 
levels of CD4+ T cell activation and proliferation. Additionally, we present data 
suggesting these effects are mediated by the increased level of TNF in uveitis patient 
sera, which appears to promote CD1c+ mDC1 maturation through the p38 MAPK 
pathway. Our data provide support for the role of blood CD1c+ mDC1, especially CD1chi 
mDC1, in the pathogenesis of non-infectious uveitis in humans. 
        Previous studies have provided strong evidence that non-infectious uveitis is an 
autoimmune disease [27]. A key step in autoimmune disease centers on mDC taking up 
self-antigens thereby initiating antigen-specific T cell immune responses. Among blood 
mDCs, CD1c+ mDC1 represent a major mDC population in the peripheral blood, and 
have been shown to be increased in other autoimmune disease such as rheumatoid 
arthritis [28]. Our study shows that CD1c+ mDC1 is increased in uveitis patients 
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compared with HCs. It should be noted from our data that the increased CD1c+ mDC1 
appear to be independent of therapy but positively correlated with disease activity [29].  
        The maturation state of DCs affects their ability to induce adaptive immune 
responses [30]. We noted that CD1c+ mDC1 from uveitis patients were more mature 
characterized by an increased expression of HLADR, although interestingly we observed 
no differences in the expression of co-stimulatory molecules (CD80 and CD86). 
Interestingly, in another study of mDCs from patients with uveitis, Kim et al did observe 
an increase in CD86. The differences may lie in the broader spectrum of DCs 
considered in their study since their isolation process selects out mDCs with subsequent 
co-staining of CD11c. This will lead to both mDC1 and mDC2 populations being included 
whereas our study was restricted to changes in the mDC1 population. Interestingly even 
in their study the changes on CD86 were relatively minor compared to the significant 
elevation in HLADR seen in both studies [8]. It remains of interest to understand why 
CD1c+ mDC1 only exhibits high HLADR but no other co-stimulatory molecules, 
particularly as alterations in relative contribution of signal 1 and signal 2 may alter 
function and differentiation of T cells [31].  
        In addition to changes in their surface phenotype, maturation is associated with a 
number of other important alterations in mDC function. Cytokine production is affected, 
with DCs displaying a different cytokine repertoire as they mature [32], and activated 
DCs becoming refractory to further stimulation due to exhaustion of their cytokine-
producing capacity [15]. In keeping with these finding, our data show that mature CD1c+ 
mDC1 from uveitis patients fail to increase their cytokine production in response to 
additional LPS stimulation in vitro.   
        It is also well established that normal DC maturation is associated with their 
transition from a phenotype with high levels of antigen uptake, to one, which primarily 
presents antigen (and has low levels of uptake). We have confirmed that this behavior is 
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also seen in the context of uveitis, with CD1c+ mDC1 in uveitis patients showing lower 
levels of antigen uptake than healthy controls, a characteristic which could also be 
induced by co-culture of MoDC with sera from uveitis patients [33]. Interestingly, we 
observed significant numbers of a CD1chi subpopulation in the uveitis patients, 
associated with a more mature phenotype, as indicated by higher HLADR expression 
and lower levels of antigen uptake, which is also supported by the study from mouse 
DCs [34]. The function of CD1 molecules is to present lipid, both endogenous and 
pathogen-derived [35]. Similar to class I MHC they associate with β2-microglobulin on 
the surface of various types of cells, particularly antigen-presenting cells (APCs), but 
differ in that (1) they are not polymorphic, and (2) have hydrophobic binding pockets that 
allow them to bind the hydrocarbon chains of lipids [36-38].  CD1c (along with CD1a and 
CD1b) is recognized by CD1-restricted T cells whereas CD1d is recognized by invariant 
natural killer T (iNKT) cells. CD1c may present a wide range of antigens and indeed its 
ability to present antigen from important human pathogens such as mycobacteria, 
leading to its proposal as a candidate for vaccine development [36]. CD1c+ mDC1 can 
be found not only in the peripheral blood but also in various tissues including the 
intestinal lamina propria [39] and in the synovial fluid in patients with rheumatoid arthritis 
[28]. In both these studies the CD1c+ mDC1 identified in the tissues express higher 
levels of activation markers than those in the peripheral blood. CD1c+ mDC1 levels can 
however be affected by treatment, as demonstrated in the study by Jolivel, et al., where 
CD1c+ mDC1 levels were reduced in laquinimod-treated multiple sclerosis patients in 
comparison to untreated patients and healthy donors [40]. However, our study supports 
that level of CD1c is not due to the treatment but is associated with disease activity. 
        A critical role of mature mDCs is to promote T cell proliferation. In our study we 
showed, as expected, that not only did uveitis patients have a higher proportion of mDC1 
with a more mature phenotype, but that (1) these mDC1 induced higher levels of T cell 
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proliferation and (2) a higher proportion of these were CD62L-. CD62L is expressed on 
naïve T cells and central memory T cells, which help T cells to localize in secondary 
lymphoid organs. Effector memory T cells do not express CD62L. They circulate in the 
periphery and have immediate effector functions upon encountering antigens [41]. It is 
likely that this lies at the center of the generation of autoimmunity in non-infectious 
uveitis. It is known that IRBP and S-antigen can initiate innate and adaptive immune 
responses by attracting immature DCs [42].  In this context our finding of increased 
levels of CD1c+ mDC1 cells in uveitis patients, is of interest, particularly in its 
implications for the generation of auto-reactive uveitic T cell immune responses, which 
may underlie the pathogenesis of noninfectious uveitis.  
        Several studies have demonstrated that TNF is increased in sera of uveitis 
patients [18-22]. We have found that TNF-treated MoDCs show lower antigen uptake 
and increase CD1c expression. TNF can promote DC maturation [43] and activate p38 
MAPK [26]. Studies have shown that SB203580 (p38 inhibitor) inhibits the up-regulation 
of CD1a, CD40, CD80, CD86, HLA-DR, and DC maturation marker CD83, which is 
induced by LPS and TNF [26]. In addition, SB203580 inhibits the enhancement of the 
allostimulatory capacity and partially prevents the down-regulation of FITC-dextran 
uptake induced by LPS and TNF [26]. Consistently, we have found that TNF 
decreases FITC-albumin antigen uptake and increases CD1c expression through 
regulating p38 MAPK. These data suggest that phosphorylation of p38 MAPK may be a 
key pathway in the maturation of DCs in uveitis. 
        In conclusion, a significant increased blood CD1c+ mDC1 with mature phenotype is 
identified in uveitis patients. A CD1chi mDC1 subpopulation is identified which is 
increased in patients and is characterized by a relatively mature phenotype including 
lower antigen uptake and increased induction of T cell responses. We also provide 
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evidence that these changes may be caused by the higher levels of TNF present in the 
serum of patients with uveitis, and which is p38 MAPK-dependent. Further 
understanding of the role of blood CD1c+ mDC1 in non-infectious uveitis may answer 
key questions regarding the initial events in the pathogenesis of uveitis and provide 
novel therapeutic opportunities for treating patients with this potentially blinding 
autoimmune disease.   
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Figure legends 
Figure 1. 
Increased frequency and number of blood CD1c+ mDC1 in uveitis patients (n=32) as 
compared to HCs (n=64). (A) Representative scattergrams from flow cytometry analysis 
of dendritic cell subtypes CD1c+ mDC1, CD141+ mDC2 and CD303+ pDCs gated on 
Lin1-HLADR+ total DCs. Percentages (B) and absolute numbers (C) of mDC1 were 
analyzed between uveitis patients and HCs. Comparison of CD1c+ mDC1 percentage in 
treated and untreated groups (D), as well as in quiescent and active uveitis groups (E). 
Student‟s t test was used in (B) and (C). One-way ANOVA analysis and post ANOVA 
analysis (Tukey‟s multiple comparisons test) were used. ANOVA p <0.0001 in (D) and 
(E).  
 
Figure 2.  
Higher HLADR expression on CD1c+ mDC1 in uveitis patients compared to HCs. (A) 
Mean fluorescence intensity (MFI) of HLADR was measured by flow cytometry between 
uveitis patients (n=37) and HCs (n=39). (B) HLADR expression on mDC1 was compared 
among untreated, treated and HC groups. (C) HLADR expression on mDC1 was 
compared in quiescent, active and HC groups. (D) HLADR expression was compared in 
untreated and treated groups of quiescent uveitis patients, and HCs. (E) HLADR 
expression was measured on mDC1 with or without LPS stimulation overnight in vitro in 
both HCs (unstimulated group; LPS group) and uveitis patients (unstimulated group; 
LPS group). Student‟s t test was used in (A). One-way ANOVA analysis and post 
ANOVA analysis (Tukey‟s multiple comparisons test) were used in (B) through (E). The 
ANOVA p values are 0.03 in (B), 0.002 in (C), 0.0003 in (D) and less than 0.0001 in (E).  
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Figure 3. 
Cytokine production of mDC1 was exhausted upon additional TLR4 stimulation in uveitis 
patients. Myeloid DC1 producing-IL6 (A), IL10 (B) and IL12P40/70 (C) were measured in 
HCs (n=9) and uveitis patients (n=12) with or without LPS stimulation in vitro. The 
cytokine production was detected by intracellular staining and analyzed by flow 
cytometry. One-way ANOVA analysis and post ANOVA analysis (Sidak‟s multiple 
comparisons test) were used. ANOVA overall p values are 0.049 (A), 0.008 (B), and 
0.039 (C). 
 
Figure 4.  
Low antigen uptake in CD1c+ mDC1 in uveitis patients. (A) Fresh blood from either HCs 
(n=23) or uveitis patients (n=30) was loaded with FITC-albumin (antigen) for 30 minutes. 
Representative antigen uptake of mDC1 measured by flow cytometry is shown. The 
negative control was MoDCs cultured in 4°C. (B) Significant differences in antigen 
uptake of mDC1 from uveitis patients and HCs. (C) CD1c+ mDC1 were separated as 
CD1chi and CD1clo mDC1 by flow cytometry. CD1chi mDC1 (D) had less antigen uptake 
when compared with CD1clo mDC1 (E). (F) CD1chi mDC1 were increased in uveitis 
patients (n=20) as compared with HCs (n=23). High CD1c expression on mDC1 
correlated with high HLADR expression in both HCs (G) and uveitis patients (H).  
 
Figure 5. 
MoDCs with lower antigen uptake enhanced CD62L-CD4+ T cell proliferation. (A) To 
address the function of mDC1 with decreased antigen uptake, monocyte-derived DC 
(MoDCs) were used in vitro. MoDCs were loaded with FITC-albumin for 30 minutes and 
sorted by flow cytometry based on high and low expression of FITC-albumin (Albumin+ 
and Albumin-). (B, C) Albumin+ or Albumin- MoDCs co-cultured with allogenic CFSE 
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labeled CD4+ T cells for 5 days. T cell proliferation and activation were measured by 
diluted expression of CFSE and low expression of CD62L. The figures are 
representative of four independent experiments. One-way ANOVA analysis was used; 
p=0.04 in (C).  
 
Figure 6. 
Treatment with uveitis sera or TNFα reduced the antigen uptake of MoDCs. (A) Antigen 
uptake assay was done in two groups: MoDCs were treated with sera from either HCs 
(HC group, n=6) or patients with uveitis (Uveitis group, n=6). The percentage of FITC-
albumin+ (B) and MFI of FITC-albumin+ (C) on MoDCs were calculated. The experiment 
was repeated six times. (D) An antigen uptake assay was done in five groups: MoDCs 
were cultured at 4C (negative control); MoDCs were cultured at 37C without TNF 
stimulation (untreated group), or with TNF stimulation overnight with different 
concentrations (0.1 ng/ml, 1 ng/ml and 10 ng/ml). The percentage of FITC-albumin+ (E) 
and MFI of FITC-albumin+ (F) on MoDCs were calculated. The dose-dependent 
experiment was repeated two times. One-way ANOVA analysis was used and the total 
p=0.0008 in (E) and 0.04 in (F).  
 
Figure 7. 
TNF increased CD1c expression by p38 MAPK signaling. (A) CD1c expression was 
measured by flow cytometry on MoDCs with (TNF group) or without (control group) 
TNF stimulation in vitro for 24 h. The experiment was repeated two times. Dotted line is 
control group; solid line is TNF group. (B) Phosphorylated p38 was measured on 
MoDCs treated with (TNF group) or without (control group) TNF for 30 minutes. The 
experiment was repeated four times. Dotted line is isotype control; Dash line is control 
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group; solid line is TNF group. (C) MoDCs were induced from monocytes by GM-CSF 
and IL-4. P38 inhibitor SB203580 was added at a concentration of 10 mol/L into the 
culture at day 0. During MoDC differentiation, CD1c expression was measured by flow 
cytometry on days 1, 3 and 5. The filled grey area is the p38 inhibitor group; and the 
solid line is the untreated group. The experiment was repeated two separate times. 
Unpaired student‟s t test was used in (A) and (B). One-way ANOVA analysis was used 
and ANOVA p<0.0001 in (D). 
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Table. Characteristics of Uveitis Patients and HCs 
Parameter Uveitis (n=74) HCs (n=96)  
Age (y), median (range) 44 (17-74) 46 (19-76) 
Gender [n (%)] 
Male 44 (59) 61 (64) 
Female 30 (41) 35 (36) 
Race [n (%)] 
        Caucasian 28 (38) 80 (83) 
         African American  28 (38) 15 (16) 
         Others  18 (24) 1 (1) 
Anatomic type of uveitis [n (%)]  N/A 
  Anterior 10 (14)  
  Intermediate 7 (9)  
  Posterior 17 (23)  
  Panuveitis  40 (54)  
Disease association [n (%)]  N/A 
  Sarcoidosis 17 (23)  
  Idiopathic 32 (43)  
  Birdshot 8 (11)  
  VKH 5 (7)  
  Behcet‟s disease 8 (11)  
  Serpiginous choroidopathy 4 (5)  
Systemic Immunosuppressive  
Therapy [n (%)] 
57 (77) N/A 
Active uveitis [n (%)] 18 (24) N/A 
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Highlights 
 CD1c+ mDC1 were increased in uveitis patients. 
 CD1c+ mDC1 exhibited less antigen uptake in uveitis patients. 
 CD1chi mDC1 subpopulation with less antigen uptake was increased in 
patients. 
 MoDCs with less antigen uptake induced more CD4+CD62L- T cells 
proliferation. 
 TNFα contribute to less antigen uptake in MoDCs through p38 MAPK 
pathway. 
